My estimate over the next 2 yes the company will generate somewhere in the order of $100m in cashflow - which when invested to establish the other lines of diagnostics will firmly establish itself in the ASX200.
STI tests are extremely hit and miss with multiple swabs blood tests to get 3 or 4 results from 12-15 that could be done in one GSS swab. STI’s are going through the roof - the data correlated with a sharp increase following app’s such as tinder - not to mention pornhub being the 15th most visited website and in the top sites across the world promoting unprotected sex, much like the Covid parties held in US colleges when people didn’t believe the risks associated with covid. These factors are accelerating the spread of STI. Unfortunately these factors are not going away
Ann: Quarterly update and Appendix 4C, page-7
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
69.0¢ |
Change
-0.025(3.50%) |
Mkt cap ! $156.5M | |||
| Open | High | Low | Value | Volume |
| 68.5¢ | 69.0¢ | 68.5¢ | $13.72K | 20.03K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8524 | 69.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 71.5¢ | 3598 | 2 |
View Market Depth
| Last trade - 15.44pm 15/11/2024 (20 minute delay) ? |
| GSS (ASX) Chart |